340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when hospitals use contract pharmacies to dispense drugs to patients.
Merck’s 340B contract pharmacy limitations will come on the heels of Boehringer Ingelheim’s
…
Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.
A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA temporarily now
…
Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in
…
The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.
U.S. Health and Human Services (HHS) Secretary
…
The U.S. Health Resources and Service Administration (HRSA) early this month invited community health centers to “resubmit a new” 340B administrative dispute resolution (ADR) petition against drug companies that deny or restrict 340B drug discounts when contract pharmacies are involved,
…
Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for arguments on
…
Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C.
The groups—American Hospital
…
The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.
…
As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue. While the proposals are going to be
…
U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on
…*Sign up for news summaries and alerts from 340B Report
